EFFECTIVENESS AND SAFETY OF INFLIXIMAB IN PATIENTS WITH EARLY AND LATE JUVENILE RHEUMATOID ARTHRITIS

• Main Authors: Е.I. Alexeeva (Author), T.V. Sleptsova (Author), S.I. Valieva (Author), T.M. Bzarova (Author), R.V. Denisova (Author), A.O. Lisitsyn (Author)
• Format: Book
• Published: "Paediatrician" Publishers LLC, 2010-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p><em>The article presents results of a study of effectiveness and safety of infliximab - monoclonal antibodies to the tumor necrotizing factor (TNF) in treatment of 100 patients11 months - 17 years old with early and late articular types of juvenile rheumatoid arthritis. The duration of treatment was 3 months - 2 years. Infliximap was delivered intravenously by scheme: infusion on 0, 2nd, 6th weeks and then every 8th week. The single dose of infliximab in patients with early rheumatoid arthritis was 6.7 (5.5; 9.0) mg/kg, with late type - 6.0 (5.0; 7.0) mg/kg of body weight. 102 weeks of treatment with anti-TNF-agent provided development of clinical remission, decrease and normalization of laboratory tests of disease's activity, total restoration of joint's function, increase of quality of life (on 97% in patients with early type, and 72% 0 in ones with late type). The drug was abolished in 39 (39%) of patients, 23% - due to the development of secondary inefficiency, and 11% - due to the development of unfavorable effects.</em><strong><em></em></strong></p><p><strong><em>Key words: children, early and late rheumatoid arthritis, treatment, infliximab.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii - </em></em>Current Pediatrics. - 2010;9(3):<em>30-42</em>)</em></span></p>

Item Description

1682-5527
1682-5535